iGENETECH Launches Platform-Based Molecular Diagnostic “Migration” Business to Build an Open Innovation Ecosystem
The MoiM platform introduces a collaborative model for reagent developers
iGENETECH has officially launched its Platform Migration Service, a platform-based business model built on its proprietary Near-PoC molecular diagnostic system, the MoiM Dx Platform, to expand B2B partnerships.The migration business model is designed as an open innovation solution for biotechnology companies that possess strong molecular diagnostic reagent technologies but face significant barriers to market entry due to the high cost and long development timelines required for dedicated diagnostic hardware.Through this initiative, iGENETECH provides partners with:Access to the MoiM Dx100/Dx200 platformTechnical support for cartridge optimization and reagent migrationRegulatory and manufacturing know-how for commercializationThis enables partner companies to deploy their reagents on a dedicated point-of-care diagnostic system without the need to develop their own diagnostic hardware, significantly reducing time-to-market.A key strength of the MoiM platform is its open protocol architecture, allowing flexible integration of reagents across a wide range of applications beyond respiratory infectious diseases, including veterinary diagnostics, food safety testing, and genetic disease screening.“We position ourselves as a platform provider, delivering validated hardware and automation technologies, while our partners focus on developing high-value diagnostic content—the reagents,” said iGENETECH.“Combined with our strategy for utilizing high-quality raw materials, shared at the Roche Diagnostics seminar, we aim to build a globally competitive molecular diagnostics ecosystem.”[Three Core Values of the iGENETECH Migration Model]SpeedEliminates the typical 3–5 year hardware development cycle, enabling immediate market entry.QualityLeverages the diagnostic precision of the MoiM platform validated through publication in Scientific Reports.ScalabilityImmediate access to a scalable platform lineup, from the compact Dx100 to the higher-throughput Dx200.
iGENETECH Launches Platform-Based Molecular Diagnostic “Migration” Business to Build an Open Innovation Ecosystem
The MoiM platform introduces a collaborative model for reagent developers
iGENETECH has officially launched its Platform Migration Service, a platform-based business model built on its proprietary Near-PoC molecular diagnostic system, the MoiM Dx Platform, to expand B2B partnerships.The migration business model is designed as an open innovation solution for biotechnology companies that possess strong molecular diagnostic reagent technologies but face significant barriers to market entry due to the high cost and long development timelines required for dedicated diagnostic hardware.Through this initiative, iGENETECH provides partners with:Access to the MoiM Dx100/Dx200 platformTechnical support for cartridge optimization and reagent migrationRegulatory and manufacturing know-how for commercializationThis enables partner companies to deploy their reagents on a dedicated point-of-care diagnostic system without the need to develop their own diagnostic hardware, significantly reducing time-to-market.A key strength of the MoiM platform is its open protocol architecture, allowing flexible integration of reagents across a wide range of applications beyond respiratory infectious diseases, including veterinary diagnostics, food safety testing, and genetic disease screening.“We position ourselves as a platform provider, delivering validated hardware and automation technologies, while our partners focus on developing high-value diagnostic content—the reagents,” said iGENETECH.“Combined with our strategy for utilizing high-quality raw materials, shared at the Roche Diagnostics seminar, we aim to build a globally competitive molecular diagnostics ecosystem.”[Three Core Values of the iGENETECH Migration Model]SpeedEliminates the typical 3–5 year hardware development cycle, enabling immediate market entry.QualityLeverages the diagnostic precision of the MoiM platform validated through publication in Scientific Reports.ScalabilityImmediate access to a scalable platform lineup, from the compact Dx100 to the higher-throughput Dx200.